Bill Poland

872 total citations
14 papers, 677 citations indexed

About

Bill Poland is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Oncology. According to data from OpenAlex, Bill Poland has authored 14 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Hematology and 3 papers in Oncology. Recurrent topics in Bill Poland's work include Renal cell carcinoma treatment (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Bill Poland is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Bill Poland collaborates with scholars based in United States, United Kingdom and Switzerland. Bill Poland's co-authors include Robert J. Motzer, Carlo L. Bello, Brett E. Houk, Lee S. Rosen, George D. Demetri, May Garrett, Yazdi K. Pithavala, Russell Wada, Janice P. Dutcher and Walter M. Stadler and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics and Drug Discovery Today.

In The Last Decade

Bill Poland

12 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bill Poland United States	10	383	277	245	142	90	14	677
J Oyee United Kingdom	17	205 0.5×	100 0.4×	266 1.1×	89 0.6×	43 0.5×	38	887
S. Swann United States	13	359 0.9×	229 0.8×	315 1.3×	41 0.3×	41 0.5×	33	696
John D. Sprandio United States	15	251 0.7×	262 0.9×	371 1.5×	236 1.7×	47 0.5×	27	989
Rosa Giuliani Italy	15	128 0.3×	166 0.6×	524 2.1×	155 1.1×	60 0.7×	31	805
Loı̈c Mourey France	16	882 2.3×	206 0.7×	565 2.3×	277 2.0×	126 1.4×	107	1.5k
Xiting Cao United States	14	248 0.6×	105 0.4×	255 1.0×	110 0.8×	44 0.5×	45	683
Ann Setser United States	9	250 0.7×	167 0.6×	456 1.9×	44 0.3×	44 0.5×	11	1.0k
Lothar Müller Germany	13	269 0.7×	163 0.6×	424 1.7×	131 0.9×	64 0.7×	71	850
James N. Frame United States	17	263 0.7×	164 0.6×	329 1.3×	77 0.5×	171 1.9×	41	995
Johanna N.H. Timmer-Bonte Netherlands	15	212 0.6×	242 0.9×	523 2.1×	71 0.5×	54 0.6×	38	910

Countries citing papers authored by Bill Poland

Since Specialization

Citations

This map shows the geographic impact of Bill Poland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bill Poland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bill Poland more than expected).

Fields of papers citing papers by Bill Poland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bill Poland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bill Poland. The network helps show where Bill Poland may publish in the future.

Co-authorship network of co-authors of Bill Poland

This figure shows the co-authorship network connecting the top 25 collaborators of Bill Poland. A scholar is included among the top collaborators of Bill Poland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bill Poland. Bill Poland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Zhang, Lu, Bill Poland, Michelle Green, Shekman Wong, & J. Greg Slatter. (2022). A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1). Xenobiotica. 52(6). 555–566. 1 indexed citations

Jiang, Xuemin, Bill Poland, Huub Jan Kleijn, et al.. (2021). Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies. Clinical and Translational Science. 14(3). 942–953. 7 indexed citations

Taylor, Adekemi, et al.. (2021). Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia. Clinical Pharmacology in Drug Development. 10(8). 918–926. 11 indexed citations

Lee, Peter, David B. Abrams, Annette M. Bachand, et al.. (2020). Estimating the Population Health Impact of Recently Introduced Modified Risk Tobacco Products: A Comparison of Different Approaches. Nicotine & Tobacco Research. 23(3). 426–437. 13 indexed citations

Poland, Bill, Qi Liu, Luna Musib, et al.. (2019). Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer. CPT Pharmacometrics & Systems Pharmacology. 8(4). 240–248. 14 indexed citations

Poland, Bill & F. A. Teischinger. (2017). Population Modeling of Modified Risk Tobacco Products Accounting for Smoking Reduction and Gradual Transitions of Relative Risk. Nicotine & Tobacco Research. 19(11). 1277–1283. 18 indexed citations

Ali, Nida, et al.. (2015). Improving health conditions in conflict-affected Liberia: A community-based approach. OakTrust (Texas A&M University Libraries).

Rini, Brian I., May Garrett, Bill Poland, et al.. (2013). Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. The Journal of Clinical Pharmacology. 53(5). 491–504. 117 indexed citations

Garrett, May, Bill Poland, Meghan Brennan, et al.. (2013). Population pharmacokinetic analysis of axitinib in healthy volunteers. British Journal of Clinical Pharmacology. 77(3). 480–492. 21 indexed citations

10.

Houk, Brett E., Carlo L. Bello, Bill Poland, et al.. (2009). Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology. 66(2). 357–371. 384 indexed citations

11.

Poland, Bill, et al.. (2009). The Clinical Utility Index as a Practical Multiattribute Approach to Drug Development Decisions. Clinical Pharmacology & Therapeutics. 86(1). 105–108. 25 indexed citations

12.

Poland, Bill, et al.. (2006). A Pharmacokinetic-Pharmacodynamic Model to Optimize the Phase IIa Development Program of Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes. 42(2). 183–191. 33 indexed citations

13.

Houk, Brett E., Michael Amantea, Robert J. Motzer, et al.. (2006). Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). 4531–4531. 5 indexed citations

14.

Poland, Bill & Russell Wada. (2001). Combining drug–disease and economic modelling to inform drug development decisions. Drug Discovery Today. 6(22). 1165–1170. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact